Welcome to our dedicated page for Sophia Genetics Sa news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on Sophia Genetics Sa stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is frequently featured in news coverage as a cloud-native healthcare technology and AI company focused on precision medicine. News about SOPHiA GENETICS often centers on its SOPHiA DDM™ Platform, an AI-powered analytics environment that analyzes complex genomic and multimodal data to generate real-time, actionable insights for hospitals, laboratories, and biopharma institutions.
On this news page, readers can follow company announcements related to financial results, platform usage, and strategic direction. Recent press releases have discussed quarterly and preliminary full-year financial performance, including revenue trends, analysis volumes on SOPHiA DDM™, and guidance updates, as well as commentary from management on growth, operating leverage, and non-IFRS metrics.
Another major category of SOPH news involves collaborations and partnerships. SOPHiA GENETICS regularly announces agreements with cancer centers, academic institutions, sequencing technology providers, and biopharma companies. Examples include collaborations to co-develop next-generation sequencing oncology tests, integrate MSK-IMPACT® and MSK-ACCESS® assays powered with SOPHiA DDM™ on external sequencing platforms, and expand access to liquid biopsy and companion diagnostics in specific markets such as Japan.
Product and technology updates also feature prominently. The company has announced the launch of SOPHiA DDM™ Digital Twins, an AI-powered research technology that creates virtual representations of patients to simulate potential outcomes in oncology. Additional news highlights include partnerships that integrate SOPHiA DDM™ with sequencing systems to create streamlined, end-to-end workflows for next-generation sequencing and precision oncology research.
Investors, clinicians, and researchers who follow SOPH news can use this page to track developments in AI-driven precision medicine, including new applications on the SOPHiA DDM™ Platform, expansions of its global customer network, and collaborations aimed at advancing cancer and rare disease research.
Summary not available.
Axalta (NYSE:AXTA) announced it won six Business Intelligence Group (BIG) Innovation Awards for product innovations across Refinish, Mobility Coatings, and Industrial Coatings on January 15, 2026. Honored products include a waterborne clearcoat that reduces solvent emissions by >65%, a low-bake OEM coatings system modeled to cut plant energy use by up to 40% and save up to $40M annually in maintenance for a 100,000-vehicle plant, and a clearcoat curing at 80°C that may lower CO2 per vehicle by ~16 kg (~20%). Other winners address EV battery fire resistance, 100% solids UV cabinet coating with zero VOCs, and electrical steel coating for high-speed motor bonding.
SOPHiA GENETICS (Nasdaq: SOPH) provided preliminary unaudited Q4 and full‑year 2025 results, issued 2026 guidance, and announced an executive transition plan.
Q4 2025: revenue of at least $21 million (+~20% YoY) and >105,000 analyses (+16% YoY). FY 2025: revenue of ~ $77 million (+~18% YoY) and a company record >391,000 analyses. FY 2026 guidance: revenue $92–94 million (~20–22% growth) and adjusted EBITDA loss $29–32 million. Leadership changes: Ross Muken promoted to CEO effective July 1, 2026; co‑founder Jurgi Camblong to transition to Executive Chairman (subject to election in June 2026). Results are preliminary and unaudited; final results expected on the March 3, 2026 earnings call.
SOPHiA GENETICS (NASDAQ: SOPH) and MD Anderson announced a strategic collaboration on January 7, 2026, to combine SOPHiA's AI analytics with MD Anderson's clinical expertise to accelerate AI-driven precision oncology.
The partners will co-develop an advanced next-generation sequencing oncology test built on the SOPHiA DDM™ Platform, create bioinformatics pipelines to interpret complex RNA-sequencing data, and launch R&D programs to track tumor evolution, improve genomic-test reproducibility, and match patients to clinical trials.
Complete Genomics and SOPHiA GENETICS (NASDAQ: SOPH) announced integration of MSK-IMPACT® and MSK-ACCESS® powered by SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform, unveiled at AMP 2025 on November 11, 2025. The collaboration offers a sample-to-report workflow for decentralized labs to scale precision oncology testing.
The DNBSEQ-T1+ delivers Q40-level accuracy, 500 million–2 billion reads per flow cell, a 24-hour paired-end 150bp run time, and can process up to 60 tumor-normal tissue pairs or 16 tumor-normal liquid biopsy pairs per flow cell at max throughput. Joint evaluation reported highly concordant variant calls, lower background noise, and reduced turnaround time versus equivalent systems.
SOPHiA GENETICS (NASDAQ: SOPH) and Complete Genomics announced a collaboration on November 11, 2025 to co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' new DNBSEQ-T1+ sequencing platform.
The integrated sample-to-report workflow targets precision oncology research by combining MSK-validated assays and AI analytics with DNBSEQ-T1+ sequencing, which delivers Q40-level accuracy, throughput of 500 million–2 billion reads per flow cell, a 24-hour PE150 run time, and capacity up to 60 tumor-normal tissue pairs or 16 tumor-normal liquid biopsy pairs per flow cell.
Joint evaluation showed high concordance in variant calls and allele frequencies, plus lower background noise and reduced turnaround time versus equivalent systems. The offering is positioned for clinical labs, cancer centers, and drug developers globally.
SOPHiA GENETICS (NASDAQ: SOPH) and Element Biosciences announced a partnership on November 11, 2025 to integrate SOPHiA DDM™ AI analytics with Element's AVITI and AVITI24 sequencing systems. The collaboration aims to deliver an end-to-end NGS workflow that combines sequencing speed and multiomic capability with AI-driven variant analysis to help clinical researchers generate actionable insights more quickly.
AVITI and AVITI24 users will gain access to SOPHiA DDM applications in oncology and rare disease, enabling local genomic research with expanded analytical tools.
SOPHiA GENETICS (Nasdaq: SOPH) reported Q3 2025 results: revenue $19.5M (+23% YoY), net IFRS loss $20.0M (+9% YoY) and adjusted EBITDA loss $10.2M (+8% YoY). Adjusted gross margin was 73.1% (adjusted basis). Excluding elevated Swiss social charges, adjusted EBITDA loss would have been $8.8M, a 13% YoY improvement.
Management raised 2025 revenue guidance to $75–$77M (growth 15–18%) and expects adjusted EBITDA loss of $39–$41M. Q3 operational highlights: 99,000 analyses (+9% YoY), 31 new customers, average contract value of new signings +180% YoY, and U.S. revenue growth of 30% YoY.
SOPHiA GENETICS (Nasdaq: SOPH) will release its third quarter 2025 financial results before U.S. markets open on Tuesday, November 4, 2025.
The company will host a conference call and webcast to discuss the results and business outlook on Nov 4, 2025 at 8:00 a.m. EDT / 2:00 p.m. CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations website and a replay will be available on the site after the call.
SOPHiA GENETICS (Nasdaq: SOPH) and A.D.A.M. Innovations announced a strategic partnership on October 16, 2025 to bring AI-powered liquid biopsy genomic testing and a companion diagnostic (CDx) to Japan.
The collaboration will launch the MSK-ACCESS® liquid biopsy application powered by SOPHiA DDM™, analyze samples in-house at A.D.A.M.'s Tokyo lab, and pursue development of a local CDx to support personalized oncology, faster turnaround times, lower patient costs, and pharmaceutical trial support. A.D.A.M. has completed over 2.8 million genomic tests and has operated in Japan for over 20 years.
FAQ
What is the current stock price of Sophia Genetics Sa (SOPH)?
What is the market cap of Sophia Genetics Sa (SOPH)?
